FDA Approves Accord’s Higher Strength Herceptin Biosimilar
The Two Approvals Pave The Way To A Launch In Early 2025
Following the FDA’s approval of A 150mg version of Accord’ Herceptin biosimilar, the US agency has now greenlit a higher 400mg strength version of the rival.
